Acorn Capital Advisors LLC Makes New $4.14 Million Investment in Mural Oncology plc (NASDAQ:MURA)

Acorn Capital Advisors LLC acquired a new position in shares of Mural Oncology plc (NASDAQ:MURA) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 1,286,079 shares of the company’s stock, valued at approximately $4,141,000. Mural Oncology makes up about 2.3% of Acorn Capital Advisors LLC’s holdings, making the stock its 14th largest position. Acorn Capital Advisors LLC owned 0.08% of Mural Oncology as of its most recent filing with the SEC.

Other hedge funds also recently added to or reduced their stakes in the company. Jane Street Group LLC purchased a new position in shares of Mural Oncology during the 4th quarter worth about $68,000. Northern Trust Corp boosted its stake in shares of Mural Oncology by 22.0% during the 4th quarter. Northern Trust Corp now owns 39,966 shares of the company’s stock valued at $129,000 after buying an additional 7,197 shares during the last quarter. Raymond James Financial Inc. bought a new position in Mural Oncology during the fourth quarter worth $181,000. Renaissance Technologies LLC grew its stake in Mural Oncology by 17.4% during the 4th quarter. Renaissance Technologies LLC now owns 238,465 shares of the company’s stock worth $768,000 after buying an additional 35,403 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Mural Oncology in the 4th quarter worth approximately $129,000. 80.21% of the stock is owned by hedge funds and other institutional investors.

Mural Oncology Price Performance

MURA opened at $2.61 on Friday. The firm has a market cap of $44.97 million, a PE ratio of -0.29 and a beta of 5.28. The stock has a 50-day moving average price of $2.59 and a 200-day moving average price of $3.32. Mural Oncology plc has a 1 year low of $0.95 and a 1 year high of $4.74.

Mural Oncology (NASDAQ:MURA) last announced its earnings results on Tuesday, March 11th. The company reported ($2.01) earnings per share for the quarter, missing the consensus estimate of ($1.96) by ($0.05). During the same quarter last year, the firm earned ($3.57) EPS. As a group, sell-side analysts anticipate that Mural Oncology plc will post -7.54 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on MURA shares. HC Wainwright decreased their target price on Mural Oncology from $18.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, March 26th. Jones Trading reiterated a “hold” rating on shares of Mural Oncology in a research report on Tuesday, March 25th. Morgan Stanley downgraded shares of Mural Oncology from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, March 25th. Finally, Raymond James lowered shares of Mural Oncology from a “strong-buy” rating to an “outperform” rating and set a $18.00 price target on the stock. in a research note on Tuesday, March 25th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $13.00.

Mural Oncology Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.